<DOC>
	<DOCNO>NCT01981499</DOCNO>
	<brief_summary>PF-05180999 phosphodiesterase-2 inhibitor hypothesize able reduce vascular permeability . The purpose study evaluate safety , tolerability , pharmacokinetics , effect histamine-induced wheal single dos PF-05180999 healthy adult subject . Histamine-induced wheal biomarkers vascular permeability .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Healthy male subject age 18 55 year No history clinicallyrelevant atopic dermatological disease Positive reaction intradermal injection histamine Subjects screen laboratory test result deviate upper and/or lower limit reference acceptable range . The exception liver function test must exceed upper limit normal . Subjects evidence , history , hepatic disorder , include acute chronic hepatitis B hepatitis C Intolerance intradermal histamine injection . Subjects dark skin ( Part B ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PF-05180999</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>histamine</keyword>
	<keyword>wheal</keyword>
	<keyword>flare</keyword>
	<keyword>migraine</keyword>
	<keyword>PDE2</keyword>
</DOC>